3,4-Methylenedioxyphentermine

Last updated

MDPH
Methylenedioxyphentermine.svg
Clinical data
Other namesMDP; MDPH; 3,4-Methylenedioxyphentermine; 3,4-Methylenedioxy-α,α-dimethylphenethylamine
Routes of
administration 		Oral [1]
Drug class Psychoactive drug
ATC code
  • None
Pharmacokinetic data
Duration of action 3–5 hours [1]
Identifiers
  • 1-(2H-1,3-benzodioxol-5-yl)-2-methylpropan-2-amine
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
Formula C11H15NO2
Molar mass 193.246 g·mol−1
3D model (JSmol)
  • NC(C)(C)CC1=CC(OCO2)=C2C=C1
  • InChI=1S/C11H15NO2/c1-11(2,12)6-8-3-4-9-10(5-8)14-7-13-9/h3-5H,6-7,12H2,1-2H3 X mark.svgN
  • Key:OIZBHKBNZXRXSM-UHFFFAOYSA-N X mark.svgN
 X mark.svgNYes check.svgY  (what is this?)    (verify)

3,4-Methylenedioxyphentermine (MDPH) is a psychoactive drug of the amphetamine family. MDPH was first synthesized by Alexander Shulgin. [1] Very little data exists about the pharmacological properties, metabolism, and toxicity of MDPH. [1]

Contents

Use and effects

In his book PiHKAL (Phenethylamines i Have Known And Loved) , the dose range is listed as 160–240 mg, and the duration as 3 to 5 hours. [1] MDPH's effects are very similar to those of MDA: they both are smooth and "stoning," and do not cause any visuals. [1] They also alter dreams and dream patterns. [1] But it is said to have none of the magic of MDMA. [1] Shulgin describes MDPH as a promoter; it promotes the effects of other drugs, similarly to 2C-D. [1]

Chemistry

Synthesis

The chemical synthesis of MDPH has been described. [1]

Analogues

The N-methyl derivative, 3,4-methylenedioxy-N-methylphentermine (MDMPH), has been described by Shulgin as lacking MDMA-like effects. [2] Accordingly, MDMPH, as well as MDPH, were found to be inactive as serotonin releasing agents in vitro . [2] [3]

Society and culture

United Kingdom

This substance is a Class A drug in the Drugs controlled by the UK Misuse of Drugs Act. [4]

See also

References

  1. 1 2 3 4 5 6 7 8 9 10 Shulgin A, Shulgin A (September 1991). PiHKAL: A Chemical Love Story. Berkeley, California: Transform Press. ISBN   0-9630096-0-5. OCLC   25627628. MDPH entry in PiHKAL
  2. 1 2 Nichols DF, Oberlender R (1990). "Structure-Activity Relationships of MDMA and Related Compounds: A New Class of Psychoactive Agents?". Ecstasy: The Clinical, Pharmacological and Neurotoxicological Effects of the Drug MDMA. Topics in the Neurosciences. Vol. 9. Boston, MA: Springer US. pp. 105–131. doi:10.1007/978-1-4613-1485-1_7. ISBN   978-1-4612-8799-5. PMID   1979214.
  3. ↑ Nichols DE, Lloyd DH, Hoffman AJ, Nichols MB, Yim GK (May 1982). "Effects of certain hallucinogenic amphetamine analogues on the release of [3H]serotonin from rat brain synaptosomes". Journal of Medicinal Chemistry. 25 (5): 530–535. doi:10.1021/jm00347a010. PMID   7086839.
  4. ↑ "UK Misuse of Drugs act 2001 Amendment summary". Isomer Design. Archived from the original on 22 October 2017. Retrieved 12 March 2014.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.